Gastrointestinal STRING Test With Oral Immunotherapy

Summary

This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.

Timeline

Start

2021-05-17

Primary completion

2024-05-17

Completion

2024-05-17

Outcome

Outcome not reported

Stopped (Enrollment): “Parent study closed to enrollment”

Drugs

Indications